Rasmussen's Encephalitis Treatment Market Size, Share, and Industry Analysis, By Treatment (Anticonvulsants, Immunomodulators, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast till 2032

Rasmussen's encephalitis also called Rasmussen syndrome is a rare medical condition affecting the central nervous system. It is marked by chronic progressive inflammation (Encephalitis) in one hemisphere of the brain. Consequently, patients may encounter recurrent episodes of uncontrolled electrical disturbances in the brain, leading to epileptic seizures (epilepsy) and gradual cerebral deterioration. It is a rare disorder affecting 2 out of 10 million people below the age of 18 years. Along with medications, surgery is another option for some patients to stabilize seizures and stop the disease progression.

The growth of the global Rasmussen's encephalitis treatment market is mainly driven by supportive regulatory bodies toward product approvals along with an increasing clinical trial landscape exploring novel treatment options.  

• For instance, in November 2016, the U.S. FDA granted Orphan Drug Designation to the anti-inflammatory drug Rituximab for the treatment of Rasmussen's encephalitis in young adults.

Moreover, the advancements in neurological research, increased awareness amongst the healthcare professionals, and the development of targeted therapies are some of the other factors influencing market growth.

Furthermore, the COVID-19 pandemic had a slightly positive impact on the global Rasmussen's encephalitis treatment market in 2020 due to the fact that some of the COVID-19-infected patients are suffering from encephalitis. Due to this, the demand for antiepileptic drugs has slightly increased during the pandemic.

Key Insights

The report covers the following key insights:

• Epidemiology of Rasmussen's Encephalitis


• Pipeline Analysis, By Key Players


• Key Industry Developments: Mergers, Acquisitions & Partnerships


• New Product Launches, By Key Players


• Impact of COVID-19 on the Rasmussen's Encephalitis Treatment Market

Segmentation

Analysis by Treatment

Based on treatment, the market is categorized into anticonvulsants, immunomodulators, and others. The immunomodulators segment accounted for a significant proportion of Rasmussen's encephalitis treatment market in 2023. The increasing regulatory approvals for biologics used to treat Rasmussen's encephalitis is one of the key factors responsible for the segment growth.

• For instance, in July 2023, Dr. Reddy's Laboratories Ltd. disclosed that the U.S. FDA had accepted its Biologics License Application (BLA) for substantive evaluation of its proposed biosimilar rituximab candidate DRL RI.

Moreover, various market players are engaged in strategic collaborations aimed at developing and launching anticonvulsants for the treatment of Rasmussen's Encephalitis in young adult patients.

• For instance, in July 2020, Cadila Pharmaceuticals Limited introduced a biosimilar, Rituximab, in the Indian market.

Regional Analysis

North America held a significant share of the global Rasmussen's encephalitis treatment market in 2023 and is expected to maintain its position over the forecast period. The region's highest growth is mainly due to the presence of well-established medical infrastructure and the extensive availability of advanced treatment options for Rasmussen's encephalitis.

Moreover, several voluntary organizations are focusing on increasing awareness regarding Rasmussen's encephalitis, thereby boosting regional market expansion.

• For example, RE Children's Project, LLC is a non-profit voluntary organization committed to raising awareness about Rasmussen's Encephalitis (RE) and supporting scientific research aimed at finding a cure. Additionally, the organization supports research focused on the rehabilitation process post-hemispherectomy surgery, a transformative brain surgery considered the sole known "cure" for the condition.

Similarly, the increasing number of regulatory approvals for the launch of effective medicines to treat Rasmussen's Encephalitis is another factor contributing to market growth across North America.

• For instance, in November 2020, Glenmark Pharmaceuticals Inc., USA, announced that it had received the U.S. FDA approval for its Tacrolimus Capsules USP, the generic version of Prograf 1 Capsules.

The increasing awareness regarding Rasmussen's encephalitis, as well as enhanced imaging techniques, have led to more accurate diagnosis rates, boosting the market for related therapies and treatments in the region.

Key Players Covered

The report includes the profiles of key players such as Genentech, Inc. (F. Hoffmann-La Roche Ltd), LEXICARE PHARMA PVT. LTD., Dr. Reddy's Laboratories Ltd., and Astellas Pharma U.S., Inc.

Key Industry Developments

• In January 2024, Eisai Co., Ltd. announced that it received marketing authorization approval from the Ministry of Health, Labour and Welfare for its antiepileptic drug Fycompa (perampanel) in Japan.


• In January 2023, Sun Pharmaceutical Industries Ltd. introduced SEZABY for the treatment of epilepsy in term and preterm infants in the U.S.


• In January 2023, Zydus Pharmaceuticals (USA) Inc. introduced Topiramate extended-release capsules in the American market. This medication is intended for the treatment of epilepsy for patients below the age of six years.

In April 2020, the Assistance Publique Hopitaux De Marseille initiated an observational study on patients with Rasmussen Encephalitis. In this study, Adalimumab was used as an investigational drug candidate to check efficacy in short-term and long-term treatment.